Salirasib
Product Specifications
UNSPSC Description
Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
Target Antigen
Autophagy; Ras
Type
Reference compound
Related Pathways
Autophagy;GPCR/G Protein;MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Salirasib.html
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(O)C1=CC=CC=C1SC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C
Molecular Weight
358.54
References & Citations
[1]Makovski V, et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
 Int J Cancer. 2012 Mar 15;130(6):1420-9.|[2]Nevo Y, et al. Chapman J. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
 PLoS One. 2011 Mar 22;6(3):e18049.|[3]Charette N, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
 Mol Cancer. 2010 Sep 22;9:256.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-14754/Salirasib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-14754/Salirasib-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
162520-00-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
